Recent Updates
Recently added Catalysts

Head and Neck Cancer: 7 biotech companies competing in the clinic

OncologyGold rushData as of 2026-09-04

Competitors7in the clinic
Median market cap$1.8Buniverse median $1.20B
Allocated capital$5.5B$29.1B competing
Phase 3 or filed05 mid, 2 early
Pure plays2this indication only
Capital rank35/299crowding rank 20

Head and Neck Cancer is both crowded and richly priced: 7 companies are in the clinic and the median one is worth $1.8B, against a universe median of $1.20B.

Crowded fields usually trade at a discount per company, so a premium in a field this deep says the market is pricing the size of the prize above the cost of the competition.

EXEL carries 50% of the $29.1B competing here, more than the other 6 companies combined.

$5.5B of allocated capital sits in Head and Neck Cancer, 35th of 299 indications, and 2 of the 7 companies are pure plays that trade on this indication alone.

Companies developing drugs for Head and Neck Cancer 7

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
EXELExelixisZanzalintinibPhase 21$14.7BNo11 3 Dec 2026
IBRXImmunityBioPD-L1 t-haNKPhase 21$8.7BNo12 31 Dec 2026
INBXInhibrx BiosciencesINBRX-106Phase 21$1.8BNo4 30 Sep 2026
BCAXBicara TherapeuticsFicerafusp alfaPhase 23$1.5BNo2 31 Dec 2026
ALXOALX Oncology HoldingsEvorpaceptPhase 22$281MNo4 31 Dec 2026
RXRXRecursion PharmaceuticalsGTAEXS617Phase 12$1.8BYes1 2 Nov 2026
STROSutro BiopharmaSTRO-004Phase 11$341MYes1 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. EXEL holds 50% of the $29.1B competing in this indication.

Why Head and Neck Cancer is a gold rush

Crowded and richly priced: six or more competitors, and the median one is worth more than the median small or mid cap biotech.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Head and Neck Cancer has 7 competitors and a median of $1.8B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Colorectal Cancer7 companies · $5.9B · median $723MKnife fightBiliary Tract Cancer4 companies · $4.6B · median $7.4BConcentrated betWell-differentiated Non-functional Neuroendocrine Tumor1 company · $4.5B · median $9.0BUncontestedOvarian Cancer9 companies · $6.7B · median $1.4BGold rushSmall Cell Lung Cancer8 companies · $6.7B · median $2.0BGold rushAcute Myeloid Leukemia15 companies · $7.0B · median $1.2BKnife fightHepatocellular Carcinoma5 companies · $7.3B · median $2.1BConcentrated betChronic Lymphocytic Leukemia4 companies · $3.7B · median $2.1BConcentrated bet

Head and Neck Cancer pipeline questions

Which biotech companies are developing drugs for Head and Neck Cancer?

7 US-listed companies in the $100M to $20B market cap band run clinical programmes in Head and Neck Cancer. The largest and most advanced are Exelixis (EXEL, Zanzalintinib, Phase 2); ImmunityBio (IBRX, PD-L1 t-haNK, Phase 2); Inhibrx Biosciences (INBX, INBRX-106, Phase 2); Bicara Therapeutics (BCAX, Ficerafusp alfa, Phase 2); ALX Oncology Holdings (ALXO, Evorpacept, Phase 2). The full list of 7 is in the table on this page.

How advanced is the Head and Neck Cancer pipeline?

Of the 7 clinical-stage programmes in Head and Neck Cancer, 0 are in Phase 3 or filed, 5 are in mid-stage development and 2 are in early-stage development.

Which company leads the Head and Neck Cancer field?

EXEL is the largest developer in Head and Neck Cancer, holding 50% of the $29.1B of market capitalisation competing in the indication. The median competitor is worth $1.8B.

When is the next Head and Neck Cancer catalyst?

The next dated catalyst in Head and Neck Cancer is INBX on 30 Sep 2026. 7 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map